Tiffany joined NEA in 2020 as part of the life sciences team where she invests in medtech, devices, and healthtech investments. She currently observes on the boards of or works with Allay Therapeutics, DOTS, FIRE1, Intrinsic, Lungpacer, Moximed, Relievant, Revelle Aesthetics, Setpoint Medical, and Willow.
Previously, Tiffany was at Kaiser Permanente Ventures where she focused on investments across digital health, medical devices, and healthcare services. Prior to KPV, she was a Senior Life Sciences Consultant at L.E.K. Consulting in their Los Angeles and London offices where she led strategic projects for medtech, biotech, life sciences, and private equity clients spanning M&A, launch and commercialization strategy, portfolio optimization, and product and geographic expansion projects. At L.E.K., she had particular expertise in oncology, allergy/immunology, precision medicine, diagnostics, and orphan indications. Tiffany has also collaborated on research leveraging brain organoid and synthetic biology models to interrogate Alzheimer’s Disease, and has had prior experience at GE Ventures and Amgen.
Tiffany received a BA in Business Economic Theory from the University of California, Los Angeles and an MBA from Harvard Business School.
- June 28, 2022